All AbMole products are for research use only, cannot be used for human consumption.
PCI-29732 is a potent, reversible BTK inhibitor. PCI-29732 blocks B cell antigen receptor (BCR)-mediated gene expression in CD20+ B cells. PCI-29732 inhibits the function of ABCG2 by competitively binding to the ATP-binding site of ABCG2 and enhances the anti-tumor efficacy of substrate chemotherapeutic agents. In vivo, PCI-29732 (20 mg/kg; p.o.; 5 times/3 days) enhances the anticancer efficacy of Topotecan in the H460/MX20 cell xenograft nude mice model.
Molecular Weight | 371.44 |
Formula | C22H21N5O |
CAS Number | 330786-25-9 |
Solubility (25°C) | DMSO ≥ 45 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Related BTK Products |
---|
BIIB129
BIIB129 is a covalent, selective inhibitor of Bruton's tyrosine kinase (BTK) capable of penetrating the blood-brain barrier. BIIB129 inhibits the activity of BTK by covalently binding to Cys481 in BTK, thereby affecting the function of B cells and myeloid cells. |
UBX-382
UBX-382 is an orally available proteolysis-targeting chimeras (PROTACs) that target BTK to inactivate B-cell receptor signaling. |
GDC-0834
GDC-0834 is a potent and selective BTK inhibitor. |
DD-03-171
DD-03-171 is a BTK, IKFZ1 and IKFZ3 degrader, the BTK IC50 a value of 5.1 nM. |
N-piperidine Ibrutinib hydrochloride
N-piperidine Ibrutinib hydrochloride is a reversible Ibrutinib derivative. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.